{"entity":{"id":"nct05736731","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","aka":[],"tldr":"A phase 1/2 trial of A2B530 in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, run by A2 Biotherapeutics Inc., active and no longer recruiting.","summary":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression is a phase 1/2 interventional study registered as NCT05736731 by A2 Biotherapeutics Inc., with 160 participants enrolled, started 2023-04-28 and due to reach its primary completion in 2026-12. Interventions recorded: A2B530.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05736731","url":"https://clinicaltrials.gov/study/NCT05736731"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","nsclc","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["tempus"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05736731","phase":"1/2","setting":"A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530, an Autologous Logic-gated Tmod™ Chimeric Antigen Receptor T Cell (CAR T), in Heterozygous HLA-A*02 Adult Subjects With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","sponsor":"A2 Biotherapeutics Inc.","enrolled":160,"outcomes":[]},"route":"/trials/nct05736731/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"tempus","kind":"company","name":"Tempus AI","route":"/companies/tempus/"}]}}